Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma

NCT00589784 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

50

Enrollment

OTHER

Sponsor class

Conditions

CNS Cancer
Meningioma
Intracranial Hemangiopericytoma
Hemangioblastoma
Neurofibromatosis

Interventions

DRUG: Sunitinib

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]